A Study of EXG102-031 in Patients With wAMD (Everest)

Inclusion Criteria:

1. Male or female, age ≥ 50 years of age;

2. Diagnosis of nAMD and current active lesion in the study eye at Screening;

3. An ETDRS BCVA letter scores between 73 and 19 letters in the study eye;

4. Response to anti-VEGF treatment during Screening;

5. The study eye must be a pseudophakic lens (post-cataract surgery status); and

6. Voluntarily agree to participate in the clinical trial, understand the trialprocedures, and be capable of signing the informed consent form before screening.

Exclusion Criteria:

1. Presence of any ocular disease or history of disease in the study eye other thannAMD that may affect central visual acuity and/or macular detection, includingretinal detachment, or in the opinion of the investigator could limit VA improvementin the study eye;

2. Presence in the study eye of CNV or macular edema due to causes other than AMD;

3. Presence in the study eye of scarring, fibrosis or atrophy involving the macula;

4. Subretinal hemorrhage accumulating in the center of the macula of the test eye, withan area of hemorrhage ≥ 4 optic disc diameters;

5. Active ocular infection in either eye;

6. Presence of advanced glaucoma or uncontrolled glaucoma in the study eye;

7. History of intraocular surgery in the study eye within 90 days of screening; or

8. Prior receipt of any ocular or systemic gene therapy agent.